Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

Fig. 2

Subgroup analyses for primary outcomes by atherosclerotic cardiovascular disease or heart failure

CAPTION: On the relative scale, HRs were consistent across all subgroups examined for all outcomes. On the absolute scale, for all outcomes, RDs were larger in patients with ASCVD compared to those without it, and in those with HF compared to those without it

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840